Online inquiry

IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10453MR)

This product GTTS-WQ10453MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10453MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12610MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ11158MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ6566MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ220MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ6374MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ11360MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ11757MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ13025MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW